Thromboembolic Events Related to Treatment with Checkpoint Inhibitors: Report of Two Cases
Despite the significant clinical benefits, checkpoint inhibition is associated with a unique spectrum of immune-related adverse events. It is sometimes difficult to distinguish some rare adverse effects from a cancer progression; thus, such effects should be reported in clinical trials to be diagnos...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Karger Publishers
2018-10-01
|
| Series: | Case Reports in Oncology |
| Subjects: | |
| Online Access: | https://www.karger.com/Article/FullText/492463 |
| _version_ | 1811327030481911808 |
|---|---|
| author | Jessica Tsukamoto Mariana Monteiro Silvana Vale Cynthia Lemos Thais Scarpelli Leticia Carvalho Daniela Pezzutti Raphael Brandão |
| author_facet | Jessica Tsukamoto Mariana Monteiro Silvana Vale Cynthia Lemos Thais Scarpelli Leticia Carvalho Daniela Pezzutti Raphael Brandão |
| author_sort | Jessica Tsukamoto |
| collection | DOAJ |
| description | Despite the significant clinical benefits, checkpoint inhibition is associated with a unique spectrum of immune-related adverse events. It is sometimes difficult to distinguish some rare adverse effects from a cancer progression; thus, such effects should be reported in clinical trials to be diagnosed by physicians. Only a few cases of arterial embolic events have been described in studies related to patients treated by immunotherapy. In this article, we report the cases of 2 patients who presented rare and severe thromboembolic events after using checkpoint inhibitors. The first case describes multiple organ embolism at the same time, associated with other autoimmune symptoms. In the second case, distal digital necrosis emerged after the initiation of immunotherapy. There is insufficient data about the real incidence of thromboembolic and rheumatological events related to checkpoint inhibition. Future trials should be done to establish preventive strategies. |
| first_indexed | 2024-04-13T14:59:26Z |
| format | Article |
| id | doaj.art-c9057a9ab4754b52ae066b330545728a |
| institution | Directory Open Access Journal |
| issn | 1662-6575 |
| language | English |
| last_indexed | 2024-04-13T14:59:26Z |
| publishDate | 2018-10-01 |
| publisher | Karger Publishers |
| record_format | Article |
| series | Case Reports in Oncology |
| spelling | doaj.art-c9057a9ab4754b52ae066b330545728a2022-12-22T02:42:21ZengKarger PublishersCase Reports in Oncology1662-65752018-10-0111364865310.1159/000492463492463Thromboembolic Events Related to Treatment with Checkpoint Inhibitors: Report of Two CasesJessica TsukamotoMariana MonteiroSilvana ValeCynthia LemosThais ScarpelliLeticia CarvalhoDaniela PezzuttiRaphael BrandãoDespite the significant clinical benefits, checkpoint inhibition is associated with a unique spectrum of immune-related adverse events. It is sometimes difficult to distinguish some rare adverse effects from a cancer progression; thus, such effects should be reported in clinical trials to be diagnosed by physicians. Only a few cases of arterial embolic events have been described in studies related to patients treated by immunotherapy. In this article, we report the cases of 2 patients who presented rare and severe thromboembolic events after using checkpoint inhibitors. The first case describes multiple organ embolism at the same time, associated with other autoimmune symptoms. In the second case, distal digital necrosis emerged after the initiation of immunotherapy. There is insufficient data about the real incidence of thromboembolic and rheumatological events related to checkpoint inhibition. Future trials should be done to establish preventive strategies.https://www.karger.com/Article/FullText/492463ImmunotherapyImmuno-oncologyThromboembolic eventsVasculitis |
| spellingShingle | Jessica Tsukamoto Mariana Monteiro Silvana Vale Cynthia Lemos Thais Scarpelli Leticia Carvalho Daniela Pezzutti Raphael Brandão Thromboembolic Events Related to Treatment with Checkpoint Inhibitors: Report of Two Cases Case Reports in Oncology Immunotherapy Immuno-oncology Thromboembolic events Vasculitis |
| title | Thromboembolic Events Related to Treatment with Checkpoint Inhibitors: Report of Two Cases |
| title_full | Thromboembolic Events Related to Treatment with Checkpoint Inhibitors: Report of Two Cases |
| title_fullStr | Thromboembolic Events Related to Treatment with Checkpoint Inhibitors: Report of Two Cases |
| title_full_unstemmed | Thromboembolic Events Related to Treatment with Checkpoint Inhibitors: Report of Two Cases |
| title_short | Thromboembolic Events Related to Treatment with Checkpoint Inhibitors: Report of Two Cases |
| title_sort | thromboembolic events related to treatment with checkpoint inhibitors report of two cases |
| topic | Immunotherapy Immuno-oncology Thromboembolic events Vasculitis |
| url | https://www.karger.com/Article/FullText/492463 |
| work_keys_str_mv | AT jessicatsukamoto thromboemboliceventsrelatedtotreatmentwithcheckpointinhibitorsreportoftwocases AT marianamonteiro thromboemboliceventsrelatedtotreatmentwithcheckpointinhibitorsreportoftwocases AT silvanavale thromboemboliceventsrelatedtotreatmentwithcheckpointinhibitorsreportoftwocases AT cynthialemos thromboemboliceventsrelatedtotreatmentwithcheckpointinhibitorsreportoftwocases AT thaisscarpelli thromboemboliceventsrelatedtotreatmentwithcheckpointinhibitorsreportoftwocases AT leticiacarvalho thromboemboliceventsrelatedtotreatmentwithcheckpointinhibitorsreportoftwocases AT danielapezzutti thromboemboliceventsrelatedtotreatmentwithcheckpointinhibitorsreportoftwocases AT raphaelbrandao thromboemboliceventsrelatedtotreatmentwithcheckpointinhibitorsreportoftwocases |